期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

环氧酶2抑制剂的疗效与安全性 新的研究结果令人鼓舞,但其危险效益比仍不清楚 被引量：1

Efficacy and safety of COX 2 inhibitors New data are encouraging but the risk:benefit ratio remains unclear
原文传递
导出
摘要 非甾体类抗炎药(NSAIDs)能够减轻机械性和炎症性关节病患者的疼痛并改善功能,同时也对其他很多疾病有效。但这些效果也付出了一定代价。在英国,每年大约有2000人死于由NSAIDs引起的上消化道病变,而且这类药物还对低位肠道、肺。
作者 Roger Jones 邓瑞雪
机构地区 Wolfson professor of general practice. Department of General Practice and Primary Care
出处 《英国医学杂志中文版》 2003年第3期133-134,共2页 The BMJ Chinese Edition
关键词 环氧酶2抑制剂 疗效 安全性 非甾体类抗炎药 罗非昔布
分类号 R971.1 [医药卫生—药品] R965.3 [医药卫生—药理学]
  • 相关文献

参考文献8

  • 1Bombardier C,Laine L,Reicin A,et al.Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.VIGOR Study Group[].The New England Journal of Medicine.2000
  • 2National Institute for Clinical Excellence.Guidance on the use of cyclo-oxyge-nase (Cox) Ⅱ selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis[]..2001
  • 3Watson DJ,Rhodes T,Cai B,Guess HA.Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis[].Archives of Internal Medicine.2002
  • 4Silverstein FE,Faich G,Goldstein JL,Simon LS,Pincus T,Whelton A,et al.Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomised controlled trial[].The Journal of The American Medical Association.2000
  • 5Mamdani M,Rochon PA,Juurlink DN,Kopp A,Anderson GN,Naglie G,et al.Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs[].British Medical Journal.2002
  • 6Ota S,Bamba H,Kato A,Kawamoto C,Yoshida Y,Fujiwara K,et al.COX-2, prostanoids and colon cancer[].Alimentary Pharmacology and Therapeutics.2002
  • 7Juni P,Rutjes AWS,Dieppe PA.Are selective COX-2 inhibitors superior to traditional non-steroidal anti-inflammatory drags[].British Medical Journal.2002
  • 8Deeks JJ,Smith LA,Bradley MD.Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials[].British Medical Journal.2002

同被引文献29

  • 1J. van Ryn,M. Pairet.Clinical experience with cyclooxygenase-2 inhibitors[J]. Inflammation Research . 1999 (5)
  • 2M erck W ithdraws V ioxx.FDA Issues Pub lic Health Advisory. www.fda.com . 2004
  • 3FDA Statem ent on the Halting of a C lin ical Trial of the Cox-2 In-h ib itor Celebrex. www.fda.gov . 2004
  • 4Topoi EJ.Failing the Pub lic Health—Rofecoxib. M erck and theFDA NEJM . 2004
  • 5Keane WF.M erck Announces Voluntary W orldw ide W ithdrfdwalofV ioxx. wwww.m erck.com . 2004
  • 6Vane JR.Inh ib ition of prostagland in synthesis as a m echan ism ofaction for asp irin-like drugs. Nature . 1971
  • 7L ipsky LP,Abram son SB,C rofford L,et al.The classification ofcyclooxygenase inh ib itors. The Journal of Rheumatology . 1998
  • 8Langman M J,Jensen DM,W atson D J,et al.Lower incidence ofclin ically evident upper-G I perforations,u lcers and b leeds in pa-tients treated w ith rofecoxib vsnonspecific cyclooxygenase inh ib i-tors. Gastroenterology . 1999
  • 9Sheng HG,Shao JY,K irkland SC,et al.Inh ib ition of human co-lon cancer cell growth by selective inh ib ition of cyclooxygenase-2. The Journal of Clinical Investigation . 1997
  • 10Scott LJ,Lanb HM.Rofecoxib. Drugs . 1999

引证文献1

二级引证文献5

英国医学杂志中文版
2003年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部